Severance and Change of Control AgreementControl Agreement • March 2nd, 2017 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 2nd, 2017 Company Industry JurisdictionThis Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of March 23, 2016 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Michael Kavanaugh, Senior Vice President, Chief Scientific Officer (“Employee”).
Severance and Change of Control AgreementControl Agreement • March 2nd, 2017 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 2nd, 2017 Company Industry JurisdictionThis Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of March 23, 2016 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Bob Goeltz, Senior Vice President, Chief Financial Officer (“Employee”).
Severance and Change of Control AgreementControl Agreement • March 2nd, 2017 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 2nd, 2017 Company Industry JurisdictionThis Severance and Change of Control Agreement (the “Agreement”) is made and entered into, effective as of March 23, 2016 (the “Effective Date”), by and between CytomX Therapeutics, Inc. a Delaware corporation (the “Company”), and Cynthia J. Ladd, Senior Vice President, General Counsel (“Employee”).